Recent advancements in the pharmacological treatment of MASLD and MASH have shown promising results, particularly with medications such as Resmetirom and Fibroblast Growth Factor 21 (FGF21) analogs. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.